Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 37 entries
Sorted by: Best Match Show Resources per page
Management of syndromic diarrhea/tricho-hepato-enteric syndrome: A review of the literature.

Intractable & rare diseases research

Fabre A, Bourgeois P, Coste ME, Roman C, Barlogis V, Badens C.
PMID: 28944135
Intractable Rare Dis Res. 2017 Aug;6(3):152-157. doi: 10.5582/irdr.2017.01040.

Syndromic diarrhea/tricho-hepato-enteric syndrome (SD/THE) is a rare disease linked to the loss of function of either TTC37 or SKIV2L, two components of the SKI complex. It is characterized by a combination of 9 signs (intractable diarrhea, hair abnormalities, facial...

Cite
Fabre A, Bourgeois P, Coste ME, et al. Management of syndromic diarrhea/tricho-hepato-enteric syndrome: A review of the literature. Intractable Rare Dis Res. 2017;6(3):152-157doi: 10.5582/irdr.2017.01040.
Fabre, A., Bourgeois, P., Coste, M. E., Roman, C., Barlogis, V., & Badens, C. (2017). Management of syndromic diarrhea/tricho-hepato-enteric syndrome: A review of the literature. Intractable & rare diseases research, 6(3), 152-157. https://doi.org/10.5582/irdr.2017.01040
Fabre, Alexandre, et al. "Management of syndromic diarrhea/tricho-hepato-enteric syndrome: A review of the literature." Intractable & rare diseases research vol. 6,3 (2017): 152-157. doi: https://doi.org/10.5582/irdr.2017.01040
Fabre A, Bourgeois P, Coste ME, Roman C, Barlogis V, Badens C. Management of syndromic diarrhea/tricho-hepato-enteric syndrome: A review of the literature. Intractable Rare Dis Res. 2017 Aug;6(3):152-157. doi: 10.5582/irdr.2017.01040. PMID: 28944135; PMCID: PMC5608923.
Copy Download .nbib Format: NLM
Therapy-related myeloid malignancies in myeloma.

Mediterranean journal of hematology and infectious diseases

Papanikolaou X, Barlogie B, Usmani SZ.
PMID: 22110897
Mediterr J Hematol Infect Dis. 2011;3(1):e2011047. doi: 10.4084/MJHID.2011.047. Epub 2011 Oct 24.

Therapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the immunomodulatory...

Cite
Papanikolaou X, Barlogie B, Usmani SZ. Therapy-related myeloid malignancies in myeloma. Mediterr J Hematol Infect Dis. 2011;3(1):e2011047doi: 10.4084/MJHID.2011.047.
Papanikolaou, X., Barlogie, B., & Usmani, S. Z. (2011). Therapy-related myeloid malignancies in myeloma. Mediterranean journal of hematology and infectious diseases, 3(1), e2011047. https://doi.org/10.4084/MJHID.2011.047
Papanikolaou, X, et al. "Therapy-related myeloid malignancies in myeloma." Mediterranean journal of hematology and infectious diseases vol. 3,1 (2011): e2011047. doi: https://doi.org/10.4084/MJHID.2011.047
Papanikolaou X, Barlogie B, Usmani SZ. Therapy-related myeloid malignancies in myeloma. Mediterr J Hematol Infect Dis. 2011;3(1):e2011047. doi: 10.4084/MJHID.2011.047. Epub 2011 Oct 24. PMID: 22110897; PMCID: PMC3219649.
Copy Download .nbib Format: NLM
Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach.

JCO precision oncology

Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S.
PMID: 30706044
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00019. Epub 2018 Aug 08.

PURPOSE: Multiple myeloma (MM) is a malignancy of plasma cells, with a median survival of 6 years. Despite recent therapeutic advancements, relapse remains mostly inevitable, and the disease is fatal in the majority of patients. A major challenge in...

Cite
Laganà A, Beno I, Melnekoff D, et al. Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precis Oncol. 2018;2018doi: 10.1200/PO.18.00019.
Laganà, A., Beno, I., Melnekoff, D., Leshchenko, V., Madduri, D., Ramdas, D., Sanchez, L., Niglio, S., Perumal, D., Kidd, B. A., Miotto, R., Shaknovich, R., Chari, A., Cho, H. J., Barlogie, B., Jagannath, S., Dudley, J. T., & Parekh, S. (2018). Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO precision oncology, 2018. https://doi.org/10.1200/PO.18.00019
Laganà, Alessandro, et al. "Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach." JCO precision oncology vol. 2018 (2018). doi: https://doi.org/10.1200/PO.18.00019
Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S. Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00019. Epub 2018 Aug 08. PMID: 30706044; PMCID: PMC6350920.
Copy Download .nbib Format: NLM
Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency.

Journal of clinical immunology

Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, Debré M, Malphettes M, Frange P, Catherinot E, Pellier I, Durieu I, Perlat A, Royer B, Quellec AL, Jeziorski E, Fischer A, Lortholary O.
PMID: 32578002
J Clin Immunol. 2020 Jul;40(5):786-787. doi: 10.1007/s10875-020-00793-8.

The original version of the article contained error regarding the presentation of the institutional authors in the PDF and html versions.

Cite
Coignard-Biehler H, Mahlaoui N, Pilmis B, et al. Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. J Clin Immunol. 2020;40(5):786-787doi: 10.1007/s10875-020-00793-8.
Coignard-Biehler, H., Mahlaoui, N., Pilmis, B., Barlogis, V., Brosselin, P., De Vergnes, N., Debré, M., Malphettes, M., Frange, P., Catherinot, E., Pellier, I., Durieu, I., Perlat, A., Royer, B., Quellec, A. L., Jeziorski, E., Fischer, A., Lortholary, O. (2020). Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. Journal of clinical immunology, 40(5), 786-787. https://doi.org/10.1007/s10875-020-00793-8
Coignard-Biehler, Hélène, et al. "Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency." Journal of clinical immunology vol. 40,5 (2020): 786-787. doi: https://doi.org/10.1007/s10875-020-00793-8
Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, Debré M, Malphettes M, Frange P, Catherinot E, Pellier I, Durieu I, Perlat A, Royer B, Quellec AL, Jeziorski E, Fischer A, Lortholary O. Correction to: A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. J Clin Immunol. 2020 Jul;40(5):786-787. doi: 10.1007/s10875-020-00793-8. PMID: 32578002.
Copy Download .nbib Format: NLM
Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.

British journal of haematology

Saultier P, Ninove L, Szepetowski S, Veneziano M, Visentin S, Barlogis V, Saba Villarroel PM, Amroun A, Loosveld M, de Lamballerie X, Chambost H.
PMID: 34337739
Br J Haematol. 2022 Jan;196(1):e1-e3. doi: 10.1111/bjh.17756. Epub 2021 Aug 01.

No abstract available.

Cite
Saultier P, Ninove L, Szepetowski S, et al. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. Br J Haematol. 2021;196(1):e1-e3doi: 10.1111/bjh.17756.
Saultier, P., Ninove, L., Szepetowski, S., Veneziano, M., Visentin, S., Barlogis, V., Saba Villarroel, P. M., Amroun, A., Loosveld, M., de Lamballerie, X., & Chambost, H. (2022). Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. British journal of haematology, 196(1), e1-e3. https://doi.org/10.1111/bjh.17756
Saultier, Paul, et al. "Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia." British journal of haematology vol. 196,1 (2022): e1-e3. doi: https://doi.org/10.1111/bjh.17756
Saultier P, Ninove L, Szepetowski S, Veneziano M, Visentin S, Barlogis V, Saba Villarroel PM, Amroun A, Loosveld M, de Lamballerie X, Chambost H. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. Br J Haematol. 2022 Jan;196(1):e1-e3. doi: 10.1111/bjh.17756. Epub 2021 Aug 01. PMID: 34337739; PMCID: PMC8444887.
Copy Download .nbib Format: NLM
Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia

Mouhieddine TH, Hieulle J, Moshier E, Richard S, Richter J, Cho HJ, Parekh S, Barlogie B, Chari A, Jagannath S, Madduri D.
PMID: 34670732
Clin Lymphoma Myeloma Leuk. 2021 Sep 11; doi: 10.1016/j.clml.2021.09.004. Epub 2021 Sep 11.

No abstract available.

Cite
Mouhieddine TH, Hieulle J, Moshier E, et al. Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021;doi: 10.1016/j.clml.2021.09.004.
Mouhieddine, T. H., Hieulle, J., Moshier, E., Richard, S., Richter, J., Cho, H. J., Parekh, S., Barlogie, B., Chari, A., Jagannath, S., & Madduri, D. (2021). Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, . https://doi.org/10.1016/j.clml.2021.09.004
Mouhieddine, Tarek H, et al. "Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma." Clinical lymphoma, myeloma & leukemia vol. (2021). doi: https://doi.org/10.1016/j.clml.2021.09.004
Mouhieddine TH, Hieulle J, Moshier E, Richard S, Richter J, Cho HJ, Parekh S, Barlogie B, Chari A, Jagannath S, Madduri D. Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Sep 11; doi: 10.1016/j.clml.2021.09.004. Epub 2021 Sep 11. PMID: 34670732.
Copy Download .nbib Format: NLM
Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.

British journal of haematology

Saultier P, Ninove L, Szepetowski S, Veneziano M, Visentin S, Barlogis V, Saba Villarroel PM, Amroun A, Loosveld M, de Lamballerie X, Chambost H.
PMID: 34337739
Br J Haematol. 2022 Jan;196(1):e1-e3. doi: 10.1111/bjh.17756. Epub 2021 Aug 01.

No abstract available.

Cite
Saultier P, Ninove L, Szepetowski S, et al. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. Br J Haematol. 2021;196(1):e1-e3doi: 10.1111/bjh.17756.
Saultier, P., Ninove, L., Szepetowski, S., Veneziano, M., Visentin, S., Barlogis, V., Saba Villarroel, P. M., Amroun, A., Loosveld, M., de Lamballerie, X., & Chambost, H. (2022). Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. British journal of haematology, 196(1), e1-e3. https://doi.org/10.1111/bjh.17756
Saultier, Paul, et al. "Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia." British journal of haematology vol. 196,1 (2022): e1-e3. doi: https://doi.org/10.1111/bjh.17756
Saultier P, Ninove L, Szepetowski S, Veneziano M, Visentin S, Barlogis V, Saba Villarroel PM, Amroun A, Loosveld M, de Lamballerie X, Chambost H. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. Br J Haematol. 2022 Jan;196(1):e1-e3. doi: 10.1111/bjh.17756. Epub 2021 Aug 01. PMID: 34337739; PMCID: PMC8444887.
Copy Download .nbib Format: NLM
Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.

Leukemia

Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, Arfeuille C, Osman J, Cassinat B, Pereira S, Anjos-Afonso F, Currie E, Ariza-McNaughton L, Barlogis V, Dalle JH, Baruchel A, Chomienne C, Cavé H, Bonnet D.
PMID: 32005921
Leukemia. 2020 Jul;34(7):1973. doi: 10.1038/s41375-020-0720-5.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Caye A, Rouault-Pierre K, Strullu M, et al. Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia. 2020;34(7):1973doi: 10.1038/s41375-020-0720-5.
Caye, A., Rouault-Pierre, K., Strullu, M., Lainey, E., Abarrategi, A., Fenneteau, O., Arfeuille, C., Osman, J., Cassinat, B., Pereira, S., Anjos-Afonso, F., Currie, E., Ariza-McNaughton, L., Barlogis, V., Dalle, J. H., Baruchel, A., Chomienne, C., Cavé, H., & Bonnet, D. (2020). Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia, 34(7), 1973. https://doi.org/10.1038/s41375-020-0720-5
Caye, Aurélie, et al. "Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment." Leukemia vol. 34,7 (2020): 1973. doi: https://doi.org/10.1038/s41375-020-0720-5
Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, Arfeuille C, Osman J, Cassinat B, Pereira S, Anjos-Afonso F, Currie E, Ariza-McNaughton L, Barlogis V, Dalle JH, Baruchel A, Chomienne C, Cavé H, Bonnet D. Correction: Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia. 2020 Jul;34(7):1973. doi: 10.1038/s41375-020-0720-5. PMID: 32005921; PMCID: PMC7608116.
Copy Download .nbib Format: NLM
Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.

British journal of haematology

Saultier P, Ninove L, Szepetowski S, Veneziano M, Visentin S, Barlogis V, Saba Villarroel PM, Amroun A, Loosveld M, de Lamballerie X, Chambost H.
PMID: 34337739
Br J Haematol. 2021 Aug 01; doi: 10.1111/bjh.17756. Epub 2021 Aug 01.

No abstract available.

Cite
Saultier P, Ninove L, Szepetowski S, et al. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. Br J Haematol. 2021;doi: 10.1111/bjh.17756.
Saultier, P., Ninove, L., Szepetowski, S., Veneziano, M., Visentin, S., Barlogis, V., Saba Villarroel, P. M., Amroun, A., Loosveld, M., de Lamballerie, X., & Chambost, H. (2021). Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. British journal of haematology, . https://doi.org/10.1111/bjh.17756
Saultier, Paul, et al. "Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17756
Saultier P, Ninove L, Szepetowski S, Veneziano M, Visentin S, Barlogis V, Saba Villarroel PM, Amroun A, Loosveld M, de Lamballerie X, Chambost H. Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia. Br J Haematol. 2021 Aug 01; doi: 10.1111/bjh.17756. Epub 2021 Aug 01. PMID: 34337739; PMCID: PMC8444887.
Copy Download .nbib Format: NLM
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.

Leukemia

Boyle EM, Rosenthal A, Ghamlouch H, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Wang Y, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Dhodapkar MV, Davies FE, Morgan GJ, van Rhee F, Walker BA.
PMID: 34365473
Leukemia. 2021 Aug 07; doi: 10.1038/s41375-021-01379-y. Epub 2021 Aug 07.

Sequencing studies have shed some light on the pathogenesis of progression from smouldering multiple myeloma (SMM) and symptomatic multiple myeloma (MM). Given the scarcity of smouldering samples, little data are available to determine which translational programmes are dysregulated and...

Cite
Boyle EM, Rosenthal A, Ghamlouch H, et al. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021;doi: 10.1038/s41375-021-01379-y.
Boyle, E. M., Rosenthal, A., Ghamlouch, H., Wang, Y., Farmer, P., Rutherford, M., Ashby, C., Bauer, M., Johnson, S. K., Wardell, C. P., Wang, Y., Hoering, A., Schinke, C., Thanendrarajan, S., Zangari, M., Barlogie, B., Dhodapkar, M. V., Davies, F. E., Morgan, G. J., van Rhee, F., & Walker, B. A. (2021). Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia, . https://doi.org/10.1038/s41375-021-01379-y
Boyle, Eileen M, et al. "Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups." Leukemia vol. (2021). doi: https://doi.org/10.1038/s41375-021-01379-y
Boyle EM, Rosenthal A, Ghamlouch H, Wang Y, Farmer P, Rutherford M, Ashby C, Bauer M, Johnson SK, Wardell CP, Wang Y, Hoering A, Schinke C, Thanendrarajan S, Zangari M, Barlogie B, Dhodapkar MV, Davies FE, Morgan GJ, van Rhee F, Walker BA. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2021 Aug 07; doi: 10.1038/s41375-021-01379-y. Epub 2021 Aug 07. PMID: 34365473.
Copy Download .nbib Format: NLM
Could CR mean cure?.

Blood

Barlogie B, Crowley J.
PMID: 21778345
Blood. 2011 Jul 21;118(3):483. doi: 10.1182/blood-2011-05-350322.

No abstract available.

Cite
Barlogie B, Crowley J. Could CR mean cure?. Blood. 2011;118(3):483doi: 10.1182/blood-2011-05-350322.
Barlogie, B., & Crowley, J. (2011). Could CR mean cure?. Blood, 118(3), 483. https://doi.org/10.1182/blood-2011-05-350322
Barlogie, Bart, and Crowley, John. "Could CR mean cure?." Blood vol. 118,3 (2011): 483. doi: https://doi.org/10.1182/blood-2011-05-350322
Barlogie B, Crowley J. Could CR mean cure?. Blood. 2011 Jul 21;118(3):483. doi: 10.1182/blood-2011-05-350322. PMID: 21778345.
Copy Download .nbib Format: NLM
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Clinical case reports

Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B.
PMID: 25838910
Clin Case Rep. 2015 Mar;3(3):183-92. doi: 10.1002/ccr3.180. Epub 2015 Feb 13.

Assiduous surveillance for genetic aberrations is necessary in patients on cytotoxic therapies to detect therapy-related myeloid neoplasms (t-MN). Current modalities include metaphase cytogenetics and FISH. Since t-MN may develop abruptly in cytogenetically normal patients, a discussion exploring additional methods...

Cite
Singh ZN, Jethava Y, Post GR, et al. Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. Clin Case Rep. 2015;3(3):183-92doi: 10.1002/ccr3.180.
Singh, Z. N., Jethava, Y., Post, G. R., Alapat, D., Sawyer, J., Waheed, S., Nair, B., Usmani, S. Z., Bailey, C., Petty, N., Van Rhee, F., & Barlogie, B. (2015). Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. Clinical case reports, 3(3), 183-92. https://doi.org/10.1002/ccr3.180
Singh, Zeba N, et al. "Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols." Clinical case reports vol. 3,3 (2015): 183-92. doi: https://doi.org/10.1002/ccr3.180
Singh ZN, Jethava Y, Post GR, Alapat D, Sawyer J, Waheed S, Nair B, Usmani SZ, Bailey C, Petty N, Van Rhee F, Barlogie B. Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols. Clin Case Rep. 2015 Mar;3(3):183-92. doi: 10.1002/ccr3.180. Epub 2015 Feb 13. PMID: 25838910; PMCID: PMC4377252.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 37 entries